News, Links and Commentary
Saturday, December 17, 2005
Wet MD Drug Retaane Approved In Australia
Australia's Therapeutic Goods Administration has approved Alcon Inc's drug Retaane for the treatment of some forms of wet age-related macular degeneration. From the Alcon Inc media release:
'Alcon Receives Approval of RETAANE(R) Suspension in Australia' (12 December 2005).
"We are pleased to gain approval of RETAANE(R) suspension in Australia for all lesions with a classic component because we believe RETAANE(R) suspension can provide retinal specialists with a unique new therapy to treat wet AMD. We will continue our efforts to gain approval of RETAANE(R) suspension in other jurisdictions, including the U.S., Europe, Canada, South Africa, New Zealand and Switzerland," said Scott Krueger, Ph.D., Alcon's vice president, R&D Pharmaceutical Development.
'Alcon Receives Approval of RETAANE(R) Suspension in Australia' (12 December 2005).
Comments:
Post a Comment
